本文選題：甲連盆腔膠囊　切入點(diǎn)：盆腔炎性疾病后遺癥　出處：《西南醫(yī)科大學(xué)》2017年碩士論文

【摘要】：目的:本研究使用甲連盆腔膠囊聯(lián)合金黃散外敷加TDP外照射治療盆腔炎性疾病后遺癥(Sequelae of pelvic inflammatory disease,SPID),觀察其對(duì)SPID濕熱瘀結(jié)證患者的臨床療效,并分析其對(duì)SPID患者血液中炎性因子TNF-ɑ及IL-10水平的影響,以探究該藥物在治療SPID中的作用機(jī)制。方法:有效納入2016年3月~2016年10月就診于我院婦產(chǎn)科門診SPID的病人,隨機(jī)分為治療組30例,對(duì)照組30例。對(duì)照組予以口服婦科千金片6片每日3次連用4周;治療組予以口服甲連盆腔膠囊5粒每日3次連用4周;兩組患者同時(shí)予以金黃散20g外敷于小腹,加TDP外照射30分鐘每天,連續(xù)治療4周,月經(jīng)期間停止外治法。采用ELISA檢測(cè)兩組患者治療前后血液中炎性因子腫瘤壞死因子(TNF-ɑ)及白介素-10(IL-10)的含量,檢查患者用藥前、停藥4周后癥狀和體征,以及輔助檢查結(jié)果,并進(jìn)行評(píng)分,全部數(shù)據(jù)的統(tǒng)計(jì)處理使用SPSS 20.0軟件。結(jié)果:1、兩組綜合療效比較:對(duì)照組治療后痊愈4人(14.3%),顯效8人(28.6%),有效10人(35.7%),無(wú)效6人(21.4%),總有效人數(shù)為22人,總有效率為78.57%;治療組治療后痊愈8人(27.6%),顯效14人(48.3%),有效4人(13.8%),無(wú)效3人(10.3%),總有效人數(shù)為26人,總有效率為89.66%;對(duì)照組與治療組綜合療效比較有統(tǒng)計(jì)學(xué)意義(P0.05),治療組綜合療效較對(duì)照組好。2、兩組中醫(yī)證候療效比較:對(duì)照組痊愈4人(14.3%),顯效10人(35.7%),有效4人(14.3%),無(wú)效10人(35.7%),總有效率人數(shù)為18人,總有效率為64.23%;治療組痊愈11人(37.9%),顯效9人(31.0%),有效5人(17.2%),無(wú)效4人(13.8%),總有效人數(shù)為25人,總有效率為86.21%;對(duì)照組與治療組中醫(yī)證候療效比較,差異有統(tǒng)計(jì)學(xué)意義(P0.05),治療組中醫(yī)證候療效較對(duì)照組好;3、兩組局部體征療效比較:對(duì)照組痊愈4人(14.3%),顯效16人(57.1%),有效1人(3.6%),無(wú)效7人(25.0%),總有效人數(shù)為21人,總有效率為75%;治療組痊愈11人(37.9%),顯效17人(58.0%),有效0人(0.0%),無(wú)效1人(3.4%),總有效人數(shù)為28人,總有效率為96.55%;對(duì)照組與治療組局部體癥療效比較有統(tǒng)計(jì)學(xué)意義(P0.05),治療組局部體癥療效較對(duì)照組好。4、兩組治療后血清炎性因子TNF-α水平的比較:對(duì)照組治療后血清TNF-α水平為24.33±4.5(pg/ml),治療組治療后血清TNF-α水平為20.33±5.67(pg/ml),治療組治療后血清TNF-α水平較對(duì)照組低,差異有統(tǒng)計(jì)學(xué)意義(P0.05),說(shuō)明治療組對(duì)降低TNF-α水平療效較對(duì)照組好。5、治療組與對(duì)照組治療后血清炎性因子IL-10水平的比較:對(duì)照組治療后血清IL-10水平為27.91±4.48(pg/ml),治療組治療后IL-10水平為39.27±7.44(pg/ml),治療組治療后血清IL-10水平較對(duì)照組高,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:1、甲連盆腔膠囊聯(lián)合外治法對(duì)SPID中濕熱瘀結(jié)證型療效明確,且較婦科千金片聯(lián)合外治法療效更佳。2、甲連盆腔膠囊聯(lián)合外治法可能通過(guò)抑制促炎性因子TNF-α的表達(dá)并促進(jìn)抗炎性因子IL-10的分泌及釋放,從而調(diào)控促炎性因子及抗炎性因子的平衡,最終改善SPID患者的預(yù)后結(jié)果。
[Abstract]:Objective: This study used a even pelvic capsule combined with Jinhuang powder plus TDP irradiation in treating sequelae of pelvic inflammatory disease (Sequelae of pelvic inflammatory disease, SPID, SPID) to observe the damp heat and blood stasis syndrome in patients with clinical efficacy, and analyzes its influence on the blood SPID in patients with inflammatory factor TNF- alpha and IL-10 levels. In order to explore the mechanism of action of the drug in the treatment of SPID. Methods: the effective in the March 2016 ~2016 year in October in our hospital obstetrics and gynecology clinic SPID patients were randomly divided into treatment group of 30 cases, 30 cases in the control group. The control group was given oral gynecological Qianjin tablets 6 tablets 3 times daily for 4 weeks; the treatment group was given even a pelvic 5 capsules orally 3 times a day for 4 weeks; two patients at the same time be Jinhuangsan 20g externally applied to the lower abdomen, plus TDP irradiation for 30 minutes a day, 4 weeks of continuous treatment, menstruation stop external treatment. The two groups were detected by ELISA treatment 鐤楀墠鍚庤娑蹭腑鐐庢，

本文編號(hào)：1688615